近日，国家药品监督管理局组织召开医疗器械上市后监管工作座谈会，聚焦提升医疗器械全生命周期监管效能。会议围绕上市后监管制度建设、不良事件监测、产品召回机制、企业主体责任落实以及智慧监管技术应用等关键议题展开深入研讨。与会专家和企业代表一致认为，随着医疗器械产业快速发展和新技术不断涌现，加强上市后监管对于保障公众用械安全、促进产业高质量发展具有重要意义。会议强调，监管部门将加快完善法规体系，强化风险预警与应急处置能力，推动建立科学、高效、协同的监管机制。同时，鼓励企业主动履行质量安全管理责任，加强产品全生命周期数据管理，积极配合监管工作。此次座谈会为构建更加完善的医疗器械上市后监管体系提供了重要思路和政策方向，标志着我国医疗器械监管正迈向更加精细化、智能化的新阶段。
Recently, the National Medical Products Administration (NMPA) convened a symposium on post-market regulation of medical devices, focusing on enhancing regulatory effectiveness throughout the product lifecycle. The meeting featured in-depth discussions on key topics including the development of post-market regulatory frameworks, adverse event monitoring, product recall mechanisms, corporate accountability, and the application of smart regulatory technologies. Experts and industry representatives agreed that, given the rapid growth of the medical device sector and the continuous emergence of new technologies, strengthening post-market oversight is crucial to ensuring public safety and promoting high-quality industry development. The NMPA emphasized its commitment to accelerating the refinement of regulatory policies, enhancing risk early-warning and emergency response capabilities, and fostering a scientific, efficient, and coordinated regulatory system. Companies were also encouraged to proactively fulfill their responsibilities for quality and safety management, improve data governance across the entire product lifecycle, and actively cooperate with regulatory authorities. This symposium provided valuable insights and strategic direction for building a more robust post-market regulatory framework, marking a significant step toward smarter and more precise medical device oversight in China.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/5522.html